Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek Elrafei, Fernando J. Camacho, James R. Rigas, Roman Perez-Soler, Rasim Gucalp

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade<sup>®</sup>) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

Medicine & Life Sciences